Summarized by Masters of Longevity from Longevity Technology.
A news article previewing a regulatory review of an inhaled therapy for progressive lung scarring, outlining trial-backed evidence and implications for care.
Key Takeaways
- The FDA accepted United Therapeutics’ supplemental application to expand nebulized Tyvaso for idiopathic pulmonary fibrosis.
- Pooled TETON‑1 and TETON‑2 results showed a 111.8 mL forced vital capacity improvement versus placebo with statistical significance.
- The FDA review is expected to conclude by late April 2027 and the drug holds orphan status for IPF.
